Literature DB >> 6222656

Evidence that abnormal platelet functions in human Chédiak-Higashi syndrome are the result of a lack of dense bodies.

F Rendu, J Breton-Gorius, M Lebret, C Klebanoff, D Buriot, C Griscelli, S Levy-Toledano, J P Caen.   

Abstract

The structure and functions of platelets from three patients with the Chédiak-Higashi syndrome were examined. Electron-microscopic observations revealed a large reduction in the number of serotonin-storage granules or dense bodies but otherwise normal ultrastructure and normal amounts of alpha-granules and catalase-positive granules. The number of mepacrine-labeled granules was also reduced. Platelets contained normal amounts of beta-thromboglobulin and Platelet Factor 4. The platelet release reaction studied with thrombin as the inducer was impaired. The serotonin uptake by the patients' platelets was low and not inhibited by reserpine, and its metabolism was increased. These findings clearly show that platelets from human Chédiak-Higashi syndrome are deficient in the storage pool of dense granule substances and suggest that this granule defect has an influence on the release mechanism of other granule constituents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222656      PMCID: PMC1916273     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  Platelet function in the Chediak-Higashi syndrome.

Authors:  G R Buchanan; R I Handin
Journal:  Blood       Date:  1976-06       Impact factor: 22.113

2.  Decreased nucleotide and serotonin storage associated with defective function in Chediak-Higashi syndrome cattle and human platelets.

Authors:  T G Bell; K M Meyers; D J Prieur; A S Fauci; S M Wolff; G A Padgett
Journal:  Blood       Date:  1976-08       Impact factor: 22.113

3.  The platelet defect associated with albumism.

Authors:  R M Hardisty; D C Mills; K Ketsa-Ard
Journal:  Br J Haematol       Date:  1972-12       Impact factor: 6.998

4.  Ultrastructure of cells in bone marrow and peripheral blood of normal mink and mink with the homologue of the Chediak-Higashi trait of humans. II. Cytoplasmic granules in eosinophils, basophils, mononuclear cells and platelets.

Authors:  W C Davis; S S Spicer; W B Greene; G A Padgett
Journal:  Am J Pathol       Date:  1971-06       Impact factor: 4.307

5.  Serotonin deficiency and prolonged bleeding in beige mice.

Authors:  J M Holland
Journal:  Proc Soc Exp Biol Med       Date:  1976-01

6.  Chediak-Higashi syndrome. Observations on the nature of the associated malignancy.

Authors:  P B Dent; L A Fish; L G White; R A Good
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

7.  Enzymatic activities, ADP-induced aggregation and survival in vivo as criteria of platelet viability during storage.

Authors:  J Caen; C Cousin; H Vainer; H Michel
Journal:  Transfusion       Date:  1967 Mar-Apr       Impact factor: 3.157

8.  A platelet abnormality in the Chediak-Higashi syndrome of man.

Authors:  J L Costa; A S Fauci; S M Wolff
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

9.  Abnormal platelet function in Chediak-Higashi syndrome.

Authors:  G J Boxer; H Holmsen; L Robkin; N U Bang; L A Boxer; R L Baehner
Journal:  Br J Haematol       Date:  1977-04       Impact factor: 6.998

10.  Studies of platelet 5-hydroxytryptamine (serotonin) in storage pool disease and albinism.

Authors:  H J Weiss; T B Tschopp; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

View more
  7 in total

Review 1.  Molecular defects that affect platelet dense granules.

Authors:  Meral Gunay-Aygun; Marjan Huizing; William A Gahl
Journal:  Semin Thromb Hemost       Date:  2004-10       Impact factor: 4.180

2.  Specific correction of impaired acid hydrolase secretion in storage pool-deficient platelets by adenosine diphosphate.

Authors:  B Lages; C A Dangelmaier; H Holmsen; H J Weiss
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

3.  Platelet dense granules begin to selectively accumulate mepacrine during proplatelet formation.

Authors:  Hayley A Hanby; Jialing Bao; Ji-Yoon Noh; Danuta Jarocha; Mortimer Poncz; Mitchell J Weiss; Michael S Marks
Journal:  Blood Adv       Date:  2017-08-22

4.  Evidence that Griscelli syndrome with neurological involvement is caused by mutations in RAB27A, not MYO5A.

Authors:  Yair Anikster; Marjan Huizing; Paul D Anderson; Diana L Fitzpatrick; Aharon Klar; Eva Gross-Kieselstein; Yackov Berkun; Gila Shazberg; William A Gahl; Haggit Hurvitz
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

5.  Griscelli disease with cerebral involvement.

Authors:  A Haraldsson; C M Weemaes; J A Bakkeren; R Happle
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

6.  Aspirin: pharmacology and clinical applications.

Authors:  Enma V Paez Espinosa; John P Murad; Fadi T Khasawneh
Journal:  Thrombosis       Date:  2011-11-17

Review 7.  Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism.

Authors:  Laura Dotta; Silvia Parolini; Alberto Prandini; Giovanna Tabellini; Maddalena Antolini; Stephen F Kingsmore; Raffaele Badolato
Journal:  Orphanet J Rare Dis       Date:  2013-10-17       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.